Floatz logo

Eloxatin

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

National Cancer Institute (NCI)Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
ETOPOSIDE
University of Washington
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB

View all 31 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →